BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34016843)

  • 1. Hsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac Fibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and c-Raf-Erk Pathways.
    Marunouchi T; Nakashima M; Ebitani S; Umezu S; Karasawa K; Yano E; Tanonaka K
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):822-829. PubMed ID: 34016843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway.
    Tamura S; Marunouchi T; Tanonaka K
    J Mol Cell Cardiol; 2019 Feb; 127():134-142. PubMed ID: 30582930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Hsp90 inhibitor on the RIP1-RIP3-MLKL pathway during the development of heart failure in mice.
    Marunouchi T; Nishiumi C; Iinuma S; Yano E; Tanonaka K
    Eur J Pharmacol; 2021 May; 898():173987. PubMed ID: 33640405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
    Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
    PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 17-AAG on the RIP1/RIP3/MLKL pathway during the development of heart failure following myocardial infarction in rats.
    Marunouchi T; Ito T; Onda S; Kyo L; Takahashi K; Uchida M; Yano E; Tanonaka K
    J Pharmacol Sci; 2021 Oct; 147(2):192-199. PubMed ID: 34384567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin attenuates the c-Raf/Erk and calcineurin-NFATc2 pathways via inhibition of Hsp90 activity during the development of heart failure.
    Marunouchi T; Fujita K; Takahashi K; Namiki S; Kyo L; Uchida M; Yano E; Tanonaka K
    J Pharmacol Sci; 2023 Jan; 151(1):17-27. PubMed ID: 36522119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
    van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
    Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
    Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
    BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7.
    Li X; Chu G; Zhu F; Zheng Z; Wang X; Zhang G; Wang F
    Exp Cell Res; 2020 Jan; 386(1):111716. PubMed ID: 31734152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The heat shock protein 90 inhibitor, 17-AAG, attenuates thioacetamide induced liver fibrosis in mice.
    Abu-Elsaad NM; Serrya MS; El-Karef AM; Ibrahim TM
    Pharmacol Rep; 2016 Apr; 68(2):275-82. PubMed ID: 26922527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HSP90 attenuates angiotensin II-induced adventitial remodelling via suppression of mitochondrial fission.
    Huang G; Cong Z; Wang X; Yuan Y; Xu R; Lu Z; Wang X; Qi J
    Cardiovasc Res; 2020 Apr; 116(5):1071-1084. PubMed ID: 31346611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
    Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
    Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
    Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
    Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
    Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Holmes JL; Sharp SY; Hobbs S; Workman P
    Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.
    Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D
    Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.
    Cohen SM; Mukerji R; Samadi AK; Zhang X; Zhao H; Blagg BS; Cohen MS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3(Suppl 3):S483-90. PubMed ID: 21837531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.